Dr Samantha Loveless
(she/her)
BSc (Cardiff), PhD (Cardiff)
Lab Manager, Division of Psychological Medicine and Clinical Neurosciences
Overview
I am currently employed as the Biorepository and Laboratory Manager for the Academic Neurology Lab based at Cardiff University's UHW campus.
My role involves the management of the Welsh Neuroscience Tissue Bank (WNRTB); the ethical approval, consent, collection, storage and allocation of neurology patient samples for the biobank, as well as other specific neurology projects (SNOWDONIA, Epilepsy-Bio) and biobanking arms of Multiple Sclerosis (MS) clinical trials (such as Octopus and DELIVER-MS), co-ordinating sample collection and distribution across multiple national and international sites.
I manage the laboratory and facilities as well as a team of research technicians for the MS research group and BRAIN Unit, supporting research into a wide range of disorders including MS, NMO, epilepsy, MND, glioblastoma, IIH.
My research focuses mainly on fluid biomarkers in MS with several collaborative papers published to date.
Publication
2025
- Tallantyre, E. C. et al. 2025. Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies. Multiple Sclerosis Journal (10.1177/13524585251330962)
- Griffiths, L. et al. 2025. Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosis. Brain Pathology (10.1111/bpa.70001)
2024
- Gelissen, L. M. et al. 2024. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration. Multiple Sclerosis and Related Disorders 90, article number: 105796. (10.1016/j.msard.2024.105796)
- Kreft, K. L. et al. 2024. Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort. Annals of Neurology 95(3), pp. 459-470. (10.1002/ana.26831)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21(1), article number: 52. (10.1186/s12974-024-03036-4)
2023
- Zaloum, S. et al. 2023. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal 29(8), pp. 979-989. (10.1177/13524585231185247)
2022
- Beesley, R. et al. 2022. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies. Multiple Sclerosis and Related Disorders 68, article number: 104121. (10.1016/j.msard.2022.104121)
- Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91(1), pp. 89-100. (10.1002/ana.26251)
2021
- Hrastelj, J. et al. 2021. CSF-resident CD4+ T-cells display a distinct gene expression profile with relevance to immune surveillance and multiple sclerosis. Brain Communications (10.1093/braincomms/fcab155)
- Hares, K. et al. 2021. KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. Journal of Neurology 268, pp. 2175-2184. (10.1007/s00415-020-10373-w)
2020
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26(14), pp. 1929-1937. (10.1177/1352458519887905)
- Naughton, M. et al. 2020. CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis. Journal of Neuroinflammation 17(1), article number: 349. (10.1186/s12974-020-02025-7)
- Anderson, V. et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417, article number: 117079. (10.1016/j.jns.2020.117079)
- Saxena, G. et al. 2020. Detecting and predicting neutralization of alemtuzumab responses in multiple sclerosis. Neurology, Neuroimmunology and Neuroinflammation 7(4), article number: e767. (10.1212/NXI.0000000000000767)
- Yeo, T. et al. 2020. A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application. Scientific Reports 10, article number: 12381. (10.1038/s41598-020-69119-3)
2019
- Castle, D., Wynford-Thomas, R., Loveless, S., Bentley, E., Howell, O. W. and Tallantyre, E. C. 2019. Using biomarkers to predict clinical outcomes in multiple sclerosis. Practical Neurology 19(4), pp. 342-349. (10.1136/practneurol-2018-002000)
- Zelek, W. M. et al. 2019. Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis 25(4), pp. 523-531. (10.1177/1352458518758927)
2018
- Muller, I. et al. 2018. Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy; evidence that TRAb may precede thyroid dysfunction by many years.. Thyroid 28(12), pp. 1682-1693. (10.1089/thy.2018.0232)
- Kopczynska, M. et al. 2018. Complement system biomarkers in epilepsy. Seizure - European Journal of Epilepsy 60, pp. 1-7. (10.1016/j.seizure.2018.05.016)
- Loveless, S. et al. 2018. Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis. Brain Pathology 28(4), pp. 507-520. (10.1111/bpa.12546)
2017
- Welton, J. L., Loveless, S., Stone, T., Von Ruhland, C., Robertson, N. and Clayton, A. 2017. Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis. Journal of Extracellular Vesicles 6(1), article number: 1369805. (10.1080/20013078.2017.1369805)
- Hakobyan, S., Luppe, S., Evans, D. R. S., Harding, K., Loveless, S., Robertson, N. P. and Morgan, B. P. 2017. Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal 23(7), pp. 946-955., article number: 135245851666900. (10.1177/1352458516669002)
2016
- Watkins, L. M. et al. 2016. Complement is activated in progressive multiple sclerosis cortical grey matter lesions. Journal of Neuroinflammation 13, article number: 161. (10.1186/s12974-016-0611-x)
2015
- Willis, M., Harding, K., Wardle, M., Pickersgill, T. P., Tomassini, V., Loveless, S. and Robertson, N. 2015. Site-specific clinical disease onset in multiple sclerosis. European Journal of Neurology 22(4), pp. 732-735. (10.1111/ene.12564)
2014
- Ingram, G. et al. 2014. Complement activation in MS: An immunohistochemical analysis. Journal of Neurology, Neurosurgery & Psychiatry 85(10), pp. e4.13. (10.1136/jnnp-2014-309236.11)
- Ingram, G. et al. 2014. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathologica Communications 2, article number: 53. (10.1186/2051-5960-2-53)
- Stewart, J. P. et al. 2014. Seroprevalence of molluscum contagiosum virus in German and UK populations. PLoS ONE 9(2), article number: e88734. (10.1371/journal.pone.0088734)
2012
- Ingram, G. et al. 2012. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Multiple Sclerosis Journal 18(10), pp. 1401-1411. (10.1177/1352458512438238)
2011
- Ingram, G., Hakobyan, S., Loveless, S., Robertson, N. and Morgan, B. P. 2011. Complement regulator factor H in multiple sclerosis. Journal of Cellular Biochemistry 112(10), pp. 2653-2654. (10.1002/jcb.23204)
2010
- Ingram, G. et al. 2010. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133(6), pp. 1602-1611. (10.1093/brain/awq085)
- Ingram, G., Bugert, J. J., Loveless, S. and Robertson, N. 2010. Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. European Journal of Neurology 17(11), pp. 1386-1389. (10.1111/j.1468-1331.2010.03083.x)
Erthyglau
- Tallantyre, E. C. et al. 2025. Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies. Multiple Sclerosis Journal (10.1177/13524585251330962)
- Griffiths, L. et al. 2025. Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosis. Brain Pathology (10.1111/bpa.70001)
- Gelissen, L. M. et al. 2024. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration. Multiple Sclerosis and Related Disorders 90, article number: 105796. (10.1016/j.msard.2024.105796)
- Kreft, K. L. et al. 2024. Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort. Annals of Neurology 95(3), pp. 459-470. (10.1002/ana.26831)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21(1), article number: 52. (10.1186/s12974-024-03036-4)
- Zaloum, S. et al. 2023. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal 29(8), pp. 979-989. (10.1177/13524585231185247)
- Beesley, R. et al. 2022. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies. Multiple Sclerosis and Related Disorders 68, article number: 104121. (10.1016/j.msard.2022.104121)
- Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91(1), pp. 89-100. (10.1002/ana.26251)
- Hrastelj, J. et al. 2021. CSF-resident CD4+ T-cells display a distinct gene expression profile with relevance to immune surveillance and multiple sclerosis. Brain Communications (10.1093/braincomms/fcab155)
- Hares, K. et al. 2021. KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. Journal of Neurology 268, pp. 2175-2184. (10.1007/s00415-020-10373-w)
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26(14), pp. 1929-1937. (10.1177/1352458519887905)
- Naughton, M. et al. 2020. CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis. Journal of Neuroinflammation 17(1), article number: 349. (10.1186/s12974-020-02025-7)
- Anderson, V. et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417, article number: 117079. (10.1016/j.jns.2020.117079)
- Saxena, G. et al. 2020. Detecting and predicting neutralization of alemtuzumab responses in multiple sclerosis. Neurology, Neuroimmunology and Neuroinflammation 7(4), article number: e767. (10.1212/NXI.0000000000000767)
- Yeo, T. et al. 2020. A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application. Scientific Reports 10, article number: 12381. (10.1038/s41598-020-69119-3)
- Castle, D., Wynford-Thomas, R., Loveless, S., Bentley, E., Howell, O. W. and Tallantyre, E. C. 2019. Using biomarkers to predict clinical outcomes in multiple sclerosis. Practical Neurology 19(4), pp. 342-349. (10.1136/practneurol-2018-002000)
- Zelek, W. M. et al. 2019. Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis 25(4), pp. 523-531. (10.1177/1352458518758927)
- Muller, I. et al. 2018. Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy; evidence that TRAb may precede thyroid dysfunction by many years.. Thyroid 28(12), pp. 1682-1693. (10.1089/thy.2018.0232)
- Kopczynska, M. et al. 2018. Complement system biomarkers in epilepsy. Seizure - European Journal of Epilepsy 60, pp. 1-7. (10.1016/j.seizure.2018.05.016)
- Loveless, S. et al. 2018. Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis. Brain Pathology 28(4), pp. 507-520. (10.1111/bpa.12546)
- Welton, J. L., Loveless, S., Stone, T., Von Ruhland, C., Robertson, N. and Clayton, A. 2017. Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis. Journal of Extracellular Vesicles 6(1), article number: 1369805. (10.1080/20013078.2017.1369805)
- Hakobyan, S., Luppe, S., Evans, D. R. S., Harding, K., Loveless, S., Robertson, N. P. and Morgan, B. P. 2017. Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal 23(7), pp. 946-955., article number: 135245851666900. (10.1177/1352458516669002)
- Watkins, L. M. et al. 2016. Complement is activated in progressive multiple sclerosis cortical grey matter lesions. Journal of Neuroinflammation 13, article number: 161. (10.1186/s12974-016-0611-x)
- Willis, M., Harding, K., Wardle, M., Pickersgill, T. P., Tomassini, V., Loveless, S. and Robertson, N. 2015. Site-specific clinical disease onset in multiple sclerosis. European Journal of Neurology 22(4), pp. 732-735. (10.1111/ene.12564)
- Ingram, G. et al. 2014. Complement activation in MS: An immunohistochemical analysis. Journal of Neurology, Neurosurgery & Psychiatry 85(10), pp. e4.13. (10.1136/jnnp-2014-309236.11)
- Ingram, G. et al. 2014. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathologica Communications 2, article number: 53. (10.1186/2051-5960-2-53)
- Stewart, J. P. et al. 2014. Seroprevalence of molluscum contagiosum virus in German and UK populations. PLoS ONE 9(2), article number: e88734. (10.1371/journal.pone.0088734)
- Ingram, G. et al. 2012. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Multiple Sclerosis Journal 18(10), pp. 1401-1411. (10.1177/1352458512438238)
- Ingram, G., Hakobyan, S., Loveless, S., Robertson, N. and Morgan, B. P. 2011. Complement regulator factor H in multiple sclerosis. Journal of Cellular Biochemistry 112(10), pp. 2653-2654. (10.1002/jcb.23204)
- Ingram, G. et al. 2010. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133(6), pp. 1602-1611. (10.1093/brain/awq085)
- Ingram, G., Bugert, J. J., Loveless, S. and Robertson, N. 2010. Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. European Journal of Neurology 17(11), pp. 1386-1389. (10.1111/j.1468-1331.2010.03083.x)
Contact Details
LovelessS1@cardiff.ac.uk
+44 29207 43454
Main Hospital Building, Floor 4th Floor, B-C Corridor, Room 80G, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
+44 29207 43454
Main Hospital Building, Floor 4th Floor, B-C Corridor, Room 80G, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN